Abstract

PURPOSE: CD5 is a T cell marker, aberrantly express in B cell chronic lymphocytic leukemia (B-CLL) and mantle cell lymphoma (MCL). Other chronic B cell malignancies including hairy cell leukemia (HCL) and B cell prolymphocytic leukemia (B-PLL) are CD5 negative or express this antigen in a weak way. In this study, CD5 expression was investigated in leukemic cells from 42 patients with chronic B cell lymphoproliferative disease. METHODS: We studied the CD5 expression in leukemic cells from 42 patients with chronic B-cell malignancies by flow cytometry. Demographic features such as age, sex and clinical date were also analyzed. RESULTS: There were 22 males and 20 females. The immunophenotyping showed that 35 cases were B-CLL, 3 B-PLL and HCL and one patient was MCL. CD5 expression was present in all B-CLL and MCL. Low expression of CD5 was observed in one patient with B-PLL and negative in all cases of HCL. CONCLUSION: Our date demonstrated that CD5 expression can help distinguish among B-CLL from HCL and B-PLL, but is similar expressed in MCL.

Highlights

  • CD5 is a T-cell marker that is expressed in B1 subset of human B lymphocytes

  • The objective of this study was designed to evaluate the diagnostic value of CD5 expression in leukemic cells from peripheral blood of 42 patients with B-cell chronic lymphoproliferative diseases

  • The white blood cells count (WBC) was longer when compared with other B-cell malignancies

Read more

Summary

Introduction

CD5 is a T-cell marker that is expressed in B1 subset of human B lymphocytes. Mature B cell malignancies, such as B-cell chronic lymphocytic leukemia (B-CLL) and mantle cell lymphoma (MCL) are mostly CD5+. Other B cell chronic lymphoproliferative disorders such as B cell prolymphocytic leukemia (B-PLL) and hairy cell leukemia (HCL) are CD5 negative or expressed low level of this antigen[1,3]. This immunological characteristic of B-CLL and MCL is an important parameter to distinct between these entities and other chronic B-cell lymphoproliferative diseases such as B-PLL and HCL. In B1 lymphocytes or resting cells, it has suggested that CD5+ B-cell may have a role in autoimmunity They are increased in some people with autoimmune diseases secreting immunoglobulin that reacts with autoantigens such as rheumatoid factor and single and double-stranded DNA (1,5).

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call